Aeon Formulations Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Aeon Formulations Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $776.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aeon Formulations Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $776.4K Trade | TransData Nexus

Aeon Formulations Private Limited

Indian Pharmaceutical Exporter · Nutritional Supplements Specialist · $776.4K Total Trade · DGFT Verified

Aeon Formulations Private Limited is an Indian pharmaceutical exporter with a total trade value of $776.4K across 3 products in 3 therapeutic categories. Based on 16 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Glucosamine ($400.0K), Everolimus ($200.0K), Dasatinib ($176.4K).

Aeon Formulations Private Limited — Export Portfolio & Destination Treemap

Aeon Formulations Private Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Aeon Formulations Private Limited? — Company Overview & Market Position

Aeon Formulations Private Limited, established on November 17, 2008, is a privately held pharmaceutical company headquartered in Chennai, Tamil Nadu, India. The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Aeon Formulations operates under the Corporate Identification Number (CIN) U33110TN2008PTC069867. As of the latest available data, the company has an authorized capital of ₹6.00 crore and a paid-up capital of ₹5.95 crore. The workforce comprises approximately 86 employees, reflecting a commitment to quality and operational excellence. The company's official website is www.aeonf.com.

What Does Aeon Formulations Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Glucosamine$400.0K 2Everolimus$200.0K

Product Portfolio — Top 3 by Export Value

Aeon Formulations Private Limited exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Glucosamine	Nutritional Supplements	$400.0K	8	3.0%	4
2	Everolimus	Immunosuppressants	$200.0K	4	0.5%	5
3	Dasatinib	Advanced Oncology	$176.4K	4	1.1%	10

Aeon Formulations Private Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $776.4K. The top category is Nutritional Supplements (51.5% of portfolio), followed by Immunosuppressants (25.8%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Aeon Formulations Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Aeon Formulations operates a state-of-the-art manufacturing facility located at R.S. No. 515/1, 515/2 & 514, 152/7, Vinayagar Koil Street, Thirubuvanaipalayam, Puducherry – 605 107, India. This plant is dedicated to the production of tablets, capsules, powder sachets, and other dosage forms, adhering to the stringent guidelines of Schedule M of the Drugs and Cosmetics Act. The facility is WHO-CGMP compliant, ensuring that manufacturing processes meet international quality standards.

3Key Leadership

The leadership team at Aeon Formulations is spearheaded by Dr. A.P. Vaitheeswaran, the Managing Director. With over two decades of experience in the pharmaceutical industry, Dr. Vaitheeswaran has been instrumental in the company's growth and strategic direction. He is also involved in various social and educational initiatives, reflecting his commitment to societal well-being. Other key directors include Ms. Vijayarani Vaitheeswaran and Mr. Ariarasudhan Vaitheeswaran, who contribute to the company's governance and strategic planning.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Aeon Formulations Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Aeon Formulations has made significant strides in expanding its presence in regulated markets. The company's manufacturing facility in Puducherry is approved by the UAE Ministry of Health, facilitating exports to the United Arab Emirates. This approval underscores the company's adherence to international quality standards and its commitment to meeting the regulatory requirements of key export markets. While specific details regarding approvals from other major markets such as the United States, European Union, United Kingdom, Australia, and Japan are not explicitly available, the company's WHO-CGMP compliance and ISO certifications suggest a foundation for potential market access in these regions.

2Emerging Markets

Aeon Formulations is actively exploring opportunities in emerging markets, including Africa, Latin America, and Southeast Asia. The company's WHO-CGMP compliance and ISO certifications position it favorably for entry into these regions. Additionally, the plant's approval by the UAE Ministry of Health indicates a readiness to meet international regulatory standards, which is crucial for accessing markets in Africa and Latin America. The company's strategic focus on these regions aligns with its goal to diversify its export portfolio and mitigate risks associated with overreliance on a single market.

Geographic Strategy

Aeon Formulations Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Aeon Formulations' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's WHO-CGMP compliance and ISO certifications indicate adherence to international quality standards, which is a prerequisite for FDA approvals. To gain FDA approval, the company would need to submit ANDAs for its generic products and DMFs for its active pharmaceutical ingredients, demonstrating bioequivalence and manufacturing quality. The absence of publicly available FDA inspection history suggests that the company may not yet have pursued or received FDA approvals for its products.

2WHO & EU GMP

Aeon Formulations' manufacturing facility is WHO-CGMP compliant, ensuring that its products meet international quality standards. The company holds ISO certifications, including ISO 9001, 14001, 18001, 22000, and FDA certifications, reflecting its commitment to quality and safety. However, specific details regarding EU Good Manufacturing Practice (GMP) certificates and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. Obtaining EU GMP certification and EDQM status would be advantageous for accessing European markets and enhancing the company's global credibility.

Aeon Formulations Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical export sector, Aeon Formulations faces competition from both domestic and international companies. While specific competitors in overlapping categories are not identified, the company's focus on Nutritional Supplements, Immunosuppressants, and Advanced Oncology positions it in markets with significant demand. The top three therapeutic categories account for 100% of the company's exports, indicating a concentrated product portfolio. To enhance its competitive position, Aeon Formulations may consider diversifying its product range and exploring additional therapeutic areas to meet a broader spectrum of market needs.

2Key Differentiators

Aeon Formulations' key differentiators include its WHO-CGMP compliant manufacturing facility, ISO certifications, and a diverse product portfolio encompassing pharmaceuticals, nutraceuticals, cosmeceuticals, and Ayurceuticals. The company's focus on innovation and quality, coupled with its commitment to ethical practices, sets it apart in the competitive pharmaceutical industry. Additionally, the plant's approval by the UAE Ministry of Health facilitates exports to the United Arab Emirates, enhancing the company's international presence.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Aeon Formulations Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Aeon Formulations demonstrates a strong track record in manufacturing and exporting pharmaceutical products, with a total export value of $776K USD across 16 shipments. The company's portfolio includes three therapeutic categories, with the top three categories—Nutritional Supplements (51.5%), Immunosuppressants (25.8%), and Advanced Oncology (22.7%)—reflecting a strategic emphasis on high-demand areas. The top five products account for 100% of exports, indicating a concentrated product portfolio. The company's WHO-CGMP compliant manufacturing facility and ISO certifications underscore its commitment to quality and reliability. However, the lack of diversification in the product portfolio suggests a potential risk due to overreliance on a limited number of products. To enhance reliability and resilience, Aeon Formulations may consider diversifying its product range and exploring additional markets.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and compliance:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration (FDA). Verification can be done through the

Frequently Asked Questions — Aeon Formulations Private Limited

How many pharmaceutical products does Aeon Formulations Private Limited export from India?

Aeon Formulations Private Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Glucosamine ($400.0K), Everolimus ($200.0K), Dasatinib ($176.4K). Total export value is $776.4K.

What is Aeon Formulations Private Limited's total pharmaceutical export value?

Aeon Formulations Private Limited's total pharmaceutical export value is $776.4K, based on 16 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Aeon Formulations Private Limited cover?

Aeon Formulations Private Limited exports across 3 therapeutic categories. The largest are Nutritional Supplements (51.5%, 1 products), Immunosuppressants (25.8%, 1 products), Advanced Oncology (22.7%, 1 products).

Get Full Aeon Formulations Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.